How One Infusion Provider Recovered Six Figures by Fighting UHC’s Prior Authorization Denials

The UHC infusion claim denial seldom occurs due to the apparent reasons. The remittance advice will state “prior authorization missing,” or “medical necessity not met,” or “service not covered at the place of service.” The truth behind the denial lies somewhere further down the chain of events. There is another level of utilization management by UHC that many providers do not understand. Retroactive authorization cancellation. Advanced notification requirements that function like prior authorization even though they carry a different name.

At Infusion Billing Services, we worked with an infusion provider that had been absorbing UHC infusion claim denial write-offs for eighteen months. Prior authorization was requested, approvals were on file, and services were medically necessary. The claims are still denied. The provider recovered six figures once the front-end gaps behind those UHC infusion claim denial patterns were closed. This case study explains five ways the UHC infusion claim denial surfaced, and how one front-end fix ended the cycle.

 

Client Snapshot

The firm was running three infusion units in two different states. The payer mix of the provider involved UnitedHealthcare commercial products, UnitedHealthcare Medicare Advantage products, and some self-funded employer plans run by UHC. Monthly claim volume averaged roughly 610 submissions. UHC represented the single largest payer at approximately 38% of volume.

The provider had a dedicated authorization team. Approvals were obtained. Authorization numbers were documented. That was the problem. The team was verifying that an authorization existed. They were not verifying that the authorization would survive UHC’s downstream policies. UHC infusion claim denial write-offs reached six figures over eighteen months. Every one of those UHC infusion claim denial instances traced back to the same front-end weakness. The authorization check stopped at approval. It never checked whether the approval would actually pay under UHC’s medical benefit drug policies.

 

Reason 1: Retroactive Authorization Cancellation After Provider Transition

Authorizations by UHC are revoked retrospectively if there is a transfer of a client from one provider to another where authorization for future treatment is requested. A new authorization request will set off an automated process that will invalidate the earlier authorization. A $12,300 Actemra infusion was denied this way despite having a valid authorization effective through October 2026.

Problem:

• A new provider’s authorization request cancelled the original authorization retroactively
• Services already rendered under the original approval lost coverage
• Staff did not know that a new authorization request could void an existing one

Fix:

• Built a front-end check that flagged when a patient’s authorization was at risk of retroactive cancellation
• Required confirmation that a new authorization request would not void coverage for pending dates of service
• Documented the original authorization and date range before any new request was submitted

This was the single largest source of UHC infusion claim denial write-offs in the provider’s data. The authorization was valid when the service was rendered. It was not valid when the claim was processed.

 

Reason 2: Site-of-Care Redirection After Authorization Approval

The Provider Administered Drugs Site of Care Policy of UHC requires that infusions be provided through either home infusion, ambulatory infusion center, or physician office, rather than through hospital outpatient department. This policy is applicable to many specialty drugs such as Actemra, IVIG, Remicade, Entyvio, and more. In a case where a patient got an infusion from a hospital outpatient facility that was not approved by UHC for the particular drug, the claim was denied despite a proper drug authorization.

Problem:

• Site-of-care approval was separate from drug authorization and was not verified
• Patients were scheduled at hospital outpatient sites UHC had not approved for the drug
• The authorization covered the medication but not the location of care

Fix:

• Added site-of-care verification to the front-end check before appointment confirmation
• Confirmed the scheduled location matched UHC’s approved site for the specific drug
• Redirected patients to approved alternate sites when the original location was excluded

This fix closed a UHC infusion claim denial gap that had been recurring for months. The drug was authorized. The site was not.

 

Reason 3: Non-Preferred Drug Step Therapy Without Documented History

UHC’s medical benefit injectable programs require a history of use of a preferred therapy before authorizing a non-preferred therapy within the same drug class. The non-preferred drug claim was denied by UHC since there was no step therapy history for the drug. The majority of the UHC infusion claim denial cases were related to infliximab drugs, whereby UHC has specified certain drugs as their preferred drugs.

Problem:

• Non-preferred drug was administered without documented preferred therapy history
• Step therapy criteria were not verified before the authorization request
• Staff assumed an authorization approval meant step therapy requirements were satisfied

Fix:

• Built a front-end check mapping each drug to its preferred or non-preferred status
• Required documented step therapy history before requesting authorization for a non-preferred drug
• Verified that the authorization request included the required step therapy documentation

This fix eliminated a category of UHC infusion claim denial that had been invisible because the authorization was approved, then later denied on step therapy grounds.

 

Reason 4: Advanced Notification Treated as Optional

UHC requires advanced notification for certain services before they are performed. Advanced notification is not the same as prior authorization, but the consequences of skipping it are similar. If the facility performs the service without confirming a coverage approval is on file, UHC may deny the facility claim. Staff at the provider had been treating advanced notification as a courtesy step rather than a requirement.

Problem:

• Advanced notification was skipped because staff believed it was optional
• The facility performed services without confirming coverage approval was on file
• Claims denied because the notification requirement was not met

Fix:

• Added advanced notification verification to the front-end check
• Required confirmation that notification was submitted and coverage approval was on file before the infusion
• Tracked notification deadlines and flagged any service that required notification but had not received it

It solved the problem of denials within UHC infusions that existed under the assumption that prior authorization was all that was necessary.

 

Reason 5: Medical Necessity Documentation Did Not Meet UHC Criteria

Criteria for the medical necessity of use of IVIG, SCIG, and other infusion services are provided by UHC. This criteria include specific medical conditions, prior failure of treatment and documentation in the medical records of the patients. The claim was rejected on the grounds of non-medical necessity in cases where the criteria were not met in the patient’s medical record.

Problem:

• Medical records did not document the specific UHC criteria for the billed service
• Staff did not know which UHC policy applied to which drug
• Criteria documentation was inconsistent between providers

Fix:

• Built a UHC policy reference mapping each drug to its applicable medical necessity criteria
• Required documented evidence of every applicable criterion before billing
• Standardized criteria documentation across all providers in the practice

This fix closed one of the most common UHC infusion claim denial patterns in the provider’s data. The service was clinically appropriate. The documentation simply did not prove it under UHC’s specific criteria.

 

How One Front-End Check Recovered Six Figures in UHC Infusion Claim Denial Write-Offs

Every one of these five reasons traced back to the same root problem. The provider was verifying that an authorization existed, not that the authorization would actually pay. UHC utilizes layers of policy built on top of the process of authorization itself. There are site-of-service policies, step therapy policies, advance notice policies, retroactive cancellation policies, and medical necessity policies that lie between the authorization and the payment.

The solution was one front end check that authenticated the authorization status and any policies of UHC that could void it. The single check authenticated the fact that the authorization would not be voided by retroactive cancellation, the site of care would conform to the UHC-approved location, step therapy had been recorded for non-preferred drugs, prior notice had been documented, and medical necessity requirements were fulfilled. Once the UHC infusion claim denial pattern was treated as a front-end verification problem rather than an appeals problem, the write-offs stopped.

 

Financial Recovery Results

The table below shows revenue recovered by denial category across the twelve-month review period. Every category of UHC infusion claim denial in this table was reduced after the front-end check went live.

Denial Scenario	Revenue Recovered	Outcome
Retroactive authorization cancellation	$82,000	Recovered via appeal
Site-of-care redirection	$54,000	Prevented
Non-preferred drug step therapy	$38,000	Prevented
Advanced notification not submitted	$26,000	Prevented
Medical necessity criteria not documented	$18,000	Prevented
Total revenue recovered	$218,000	Combined outcome

 

Metric	Before Fix	After Fix
UHC infusion claim denial rate	11.4%	2.1%
Claims verified against UHC policy before submission	47%	96%
Average time to catch a UHC policy gap	27 days	2 days
Overall reduction in this denial pattern	0%	82%

These results confirm that one front-end check resolved several UHC infusion claim denial patterns at once. Fragmented authorization verification had been the root cause all along. The provider did not recover the six figures by appealing every denied claim. It recovered the money by preventing the UHC infusion claim denial before the claim was submitted.

 

Key Takeaways

These lessons help infusion practices prevent recurring UHC infusion claim denials.

• Confirm that a new authorization request will not retroactively cancel coverage for pending services
• Verify site-of-care approval separately from drug authorization
• Document step therapy history before requesting authorization for non-preferred drugs
• Treat advanced notification as a requirement, not a courtesy
• Map every drug to its applicable UHC medical necessity criteria before billing

 

Conclusion

A UHC infusion claim denial is rarely what it appears to be. The authorization was approved. The drug was medically necessary. The site was clinically appropriate. UHC denied the claim despite the existence of a layer of coverage behind the authorization that was dissatisfied. Retroactive cancellation, site-of-care redirecting, step therapy, advanced notice requirements, and medical necessity all lead to the same thing. The claim is denied, and the UHC infusion claim denial rate increases.

One front-end check recovered $218,000 in UHC infusion claim denial write-offs and cut the denial rate from 11.4% to 2.1%. The provider did not need more appeals staff. It needed authorization verification that checked UHC’s full policy stack instead of just the approval letter. If your infusion practice is writing off claims to UHC infusion claim denials, the fix is upstream. A UHC infusion claim denial is preventable, and one front-end check is often all it takes to stop it. Contact Infusion Billing Services today for a UHC authorization and policy audit. One front-end check can end UHC infusion claim denials before they start.